Please note Gluten Detect is formerly known as Gluten Detective.
- To investigate the association of gluten exposure with symptoms and levels of serological markers.
- Study on the efficacy of AMG 714. This treatment is the first monoclonal anti-IL-15 antibody to be used to investigate the treatment of celiac disease.
- To assess the performance of enzyme-linked immunosorbent assay (ELISA) and point-of-care tests (PoCTs) for Gluten immunogenic peptides (GIP) excretion in celiac disease patients on gluten-free diet (GFD).
- To evaluate the usefulness of fecal gluten immunogenic peptides to support the diagnosis and to determine the adherence to the gluten-free diet in celiac disease.
- Estimates of the mean and average gluten intake through the determination of GIP excreted in feces and urine.
- To analyze prior clinical data to determine how much gluten is accidentally consumed while on a gluten free diet. To understand the range of gluten consumption for a wide distribution of celiac disease patients.
(2018) The Dietary Intervention of Transgenic Low-Gliadin Wheat Bread in Patients with Non-Celiac Gluten Sensitivity (NCGS) Showed No Differences with Gluten Free Diet (GFD) but Provides Better Gut Microbiota Profile
- To evaluate the effectiveness of bread made with low-gliadin flour from the E82 line of wheat.
- To assess the excretion of gluten in relation to the amount of gluten ingested in healthy pediatric volunteers with different diets.
- Determine GIP levels in food, feces, and urine samples, to assess the relationship of gluten intake to intestinal villous atrophy and gluten excretion.
- To assess the sensitivity and specificity of a rapid immunochromatographic (IC) test that detects gluten-containing immunogenic peptides (GIP) in faces, compared to an enzyme-linked immunosorbent assay (ELISA) method.
- Review the literature on coeliac disease therapeutic trials and issue recommendations for outcome measures.
- Recent gluten intake was measured by GIP in CD children and compared to routine clinical measures to evaluate GFD compliance.
- Validation of a urine method to determine gluten intake and monitor GFD compliance in patients with CD and to evaluate its correlation with mucosal damage.
- Evaluate the recent literature relating to CD and the monitoring of GFD.
- Evaluate the measurement of gluten immunogenic peptides (GIP) in stools as a marker of GFD adherence in CD patients and compare it with traditional methods of GFD monitoring.
- To evaluate a method to determine gluten intake and monitor compliance with GFD in patients with celiac disease and to assess its correlation with damage to the intestinal mucosa.
- Assess the capacity to determine gluten ingestion and monitor GFD compliance in celiac patients by the detection of gluten and gliadin 33-mer equivalent peptidic epitopes (33EPs) in human feces.